Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemziviptadil
- Development stage
- Phase 2
- Lead developer
- ImmunoForge
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pemziviptadil is a long-acting recombinant fusion protein analogue of vasoactive intestinal peptide (VIP), designed for once-weekly subcutaneous administration. It consists of VIP fused to an elastin-like polypeptide (ELP) biopolymer to extend its half-life and improve pharmacokinetics. Pemziviptadil acts as a selective agonist at the vasoactive intestinal peptide receptor 2 (VPAC2), increasing both cardiac contraction and relaxation while avoiding gastrointestinal side effects associated with VPAC1 activation. The drug is being developed for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD), pulmonary arterial hypertension (PAH), heart failure, and other cardiovascular diseases. It has received orphan drug designation from the US FDA for PAH and DMD cardiomyopathy[1][7][8][10].
- Brand names
- Vasomera
- Other names
- pemziviptadilPB 1046PB1046PB-1046PF1804PF-1804PF 1804Vasomera
02
Targets
VIPR2 (Vasoactive intestinal polypeptide receptor 2)
Beyond the preview
Go deeper on pemziviptadil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemziviptadil.